| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Neoplasms | 20 | 2026 | 323 | 3.920 |
Why?
|
| Meningioma | 7 | 2026 | 65 | 3.430 |
Why?
|
| Glioblastoma | 11 | 2022 | 161 | 2.930 |
Why?
|
| Meningeal Neoplasms | 7 | 2026 | 63 | 2.920 |
Why?
|
| Tumor Suppressor Proteins | 4 | 2026 | 211 | 1.330 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2026 | 256 | 1.160 |
Why?
|
| Galectin 3 | 1 | 2026 | 9 | 0.970 |
Why?
|
| Myasthenia Gravis | 1 | 2026 | 12 | 0.950 |
Why?
|
| Neuromuscular Diseases | 1 | 2026 | 24 | 0.940 |
Why?
|
| Transcranial Direct Current Stimulation | 1 | 2026 | 20 | 0.940 |
Why?
|
| Antineoplastic Agents, Alkylating | 4 | 2020 | 33 | 0.940 |
Why?
|
| DNA Modification Methylases | 3 | 2026 | 19 | 0.870 |
Why?
|
| DNA Repair Enzymes | 3 | 2026 | 39 | 0.860 |
Why?
|
| Cyclin-Dependent Kinase 6 | 2 | 2020 | 12 | 0.800 |
Why?
|
| Cyclin-Dependent Kinase 4 | 2 | 2020 | 18 | 0.800 |
Why?
|
| Benzimidazoles | 2 | 2020 | 55 | 0.770 |
Why?
|
| Ependymoma | 3 | 2021 | 5 | 0.740 |
Why?
|
| Central Nervous System Neoplasms | 3 | 2024 | 39 | 0.730 |
Why?
|
| Glioma | 5 | 2022 | 101 | 0.720 |
Why?
|
| Antimetabolites, Antineoplastic | 3 | 2019 | 42 | 0.700 |
Why?
|
| Neurofibromin 2 | 2 | 2022 | 4 | 0.690 |
Why?
|
| Astrocytoma | 2 | 2026 | 14 | 0.680 |
Why?
|
| Checkpoint Kinase 2 | 1 | 2020 | 28 | 0.640 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2020 | 26 | 0.630 |
Why?
|
| Quinolones | 1 | 2020 | 25 | 0.630 |
Why?
|
| Cell Line, Tumor | 5 | 2026 | 1573 | 0.620 |
Why?
|
| Lanosterol | 1 | 2019 | 4 | 0.620 |
Why?
|
| Triterpenes | 1 | 2019 | 7 | 0.620 |
Why?
|
| Heptanoic Acids | 1 | 2019 | 22 | 0.610 |
Why?
|
| Piperazines | 1 | 2020 | 86 | 0.610 |
Why?
|
| Phosphatidylinositol 3-Kinases | 4 | 2020 | 178 | 0.600 |
Why?
|
| Pharmaceutical Preparations | 1 | 2020 | 126 | 0.590 |
Why?
|
| Pyridines | 1 | 2020 | 120 | 0.580 |
Why?
|
| Allyl Compounds | 1 | 2018 | 4 | 0.570 |
Why?
|
| Sulfides | 1 | 2018 | 22 | 0.560 |
Why?
|
| Humans | 47 | 2026 | 65845 | 0.560 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2018 | 38 | 0.560 |
Why?
|
| Bevacizumab | 2 | 2020 | 61 | 0.550 |
Why?
|
| Histone Deacetylases | 1 | 2018 | 67 | 0.540 |
Why?
|
| Antineoplastic Agents | 2 | 2020 | 645 | 0.540 |
Why?
|
| Methotrexate | 2 | 2017 | 81 | 0.540 |
Why?
|
| Spinal Cord Diseases | 2 | 2017 | 44 | 0.540 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2026 | 203 | 0.540 |
Why?
|
| Magnetic Resonance Imaging | 8 | 2017 | 2324 | 0.520 |
Why?
|
| Middle Aged | 23 | 2026 | 18501 | 0.490 |
Why?
|
| Gliosarcoma | 1 | 2015 | 7 | 0.460 |
Why?
|
| Cytarabine | 1 | 2015 | 36 | 0.440 |
Why?
|
| Supratentorial Neoplasms | 1 | 2014 | 2 | 0.440 |
Why?
|
| Rosette Formation | 1 | 2014 | 12 | 0.440 |
Why?
|
| Cerebral Ventricle Neoplasms | 1 | 2014 | 3 | 0.430 |
Why?
|
| Ganglioglioma | 1 | 2014 | 4 | 0.430 |
Why?
|
| Male | 27 | 2026 | 31410 | 0.430 |
Why?
|
| Cell Proliferation | 4 | 2026 | 1044 | 0.430 |
Why?
|
| Seizures | 3 | 2021 | 141 | 0.430 |
Why?
|
| Meningitis, Cryptococcal | 1 | 2014 | 14 | 0.430 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2014 | 33 | 0.430 |
Why?
|
| Aged | 17 | 2026 | 15147 | 0.430 |
Why?
|
| Sarcoma | 1 | 2014 | 36 | 0.420 |
Why?
|
| Transcription Factor RelA | 1 | 2014 | 51 | 0.420 |
Why?
|
| Middle Cerebral Artery | 1 | 2014 | 53 | 0.410 |
Why?
|
| Mutation | 5 | 2026 | 2675 | 0.410 |
Why?
|
| Female | 24 | 2026 | 34425 | 0.410 |
Why?
|
| Brain Diseases, Metabolic, Inborn | 1 | 2013 | 6 | 0.410 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2020 | 218 | 0.400 |
Why?
|
| Olivary Nucleus | 1 | 2013 | 3 | 0.400 |
Why?
|
| Cryptococcosis | 1 | 2014 | 75 | 0.400 |
Why?
|
| Neoplasm Proteins | 1 | 2015 | 286 | 0.400 |
Why?
|
| Thrombocytopenia | 1 | 2014 | 59 | 0.390 |
Why?
|
| Memory | 1 | 2014 | 124 | 0.390 |
Why?
|
| Cryptococcus neoformans | 1 | 2014 | 142 | 0.390 |
Why?
|
| Brain | 4 | 2020 | 1672 | 0.380 |
Why?
|
| Lymphoma | 1 | 2013 | 101 | 0.380 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2014 | 503 | 0.380 |
Why?
|
| Muscle Weakness | 1 | 2012 | 33 | 0.370 |
Why?
|
| DNA Methylation | 3 | 2026 | 307 | 0.370 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2022 | 378 | 0.370 |
Why?
|
| Muscular Atrophy, Spinal | 1 | 2012 | 25 | 0.360 |
Why?
|
| Developmental Disabilities | 1 | 2013 | 119 | 0.360 |
Why?
|
| Cognition Disorders | 1 | 2013 | 224 | 0.360 |
Why?
|
| Apoptosis | 4 | 2020 | 1100 | 0.330 |
Why?
|
| Dementia | 1 | 2014 | 290 | 0.330 |
Why?
|
| bcl-2-Associated X Protein | 2 | 2020 | 48 | 0.310 |
Why?
|
| Adult | 17 | 2026 | 17579 | 0.310 |
Why?
|
| Proteins | 1 | 2014 | 764 | 0.290 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2020 | 216 | 0.280 |
Why?
|
| Stroke | 2 | 2015 | 1225 | 0.280 |
Why?
|
| Astrocytes | 2 | 2020 | 123 | 0.280 |
Why?
|
| Isocitrate Dehydrogenase | 3 | 2020 | 28 | 0.270 |
Why?
|
| Mice, SCID | 2 | 2019 | 518 | 0.270 |
Why?
|
| Survival Analysis | 3 | 2020 | 579 | 0.260 |
Why?
|
| Coculture Techniques | 1 | 2026 | 104 | 0.240 |
Why?
|
| Chemoradiotherapy | 2 | 2016 | 75 | 0.230 |
Why?
|
| HIV Infections | 1 | 2012 | 961 | 0.230 |
Why?
|
| Electroencephalography | 3 | 2021 | 156 | 0.230 |
Why?
|
| Peripheral Nervous System Diseases | 2 | 2015 | 28 | 0.220 |
Why?
|
| Rituximab | 2 | 2015 | 89 | 0.210 |
Why?
|
| Neoplasm Grading | 2 | 2026 | 102 | 0.210 |
Why?
|
| Biomarkers, Tumor | 2 | 2026 | 527 | 0.210 |
Why?
|
| Neurofibromatosis 2 | 1 | 2024 | 3 | 0.210 |
Why?
|
| Mice | 3 | 2026 | 11185 | 0.210 |
Why?
|
| Neuroma, Acoustic | 1 | 2024 | 8 | 0.210 |
Why?
|
| Ki-67 Antigen | 2 | 2015 | 37 | 0.210 |
Why?
|
| Aminopyridines | 2 | 2022 | 34 | 0.200 |
Why?
|
| Lung Neoplasms | 2 | 2026 | 712 | 0.200 |
Why?
|
| Combined Modality Therapy | 3 | 2020 | 375 | 0.200 |
Why?
|
| Animals | 5 | 2026 | 21493 | 0.200 |
Why?
|
| Neurons | 2 | 2020 | 935 | 0.200 |
Why?
|
| Retrospective Studies | 8 | 2024 | 6957 | 0.200 |
Why?
|
| Clinical Trials as Topic | 4 | 2019 | 462 | 0.180 |
Why?
|
| Promoter Regions, Genetic | 2 | 2026 | 690 | 0.170 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2020 | 466 | 0.170 |
Why?
|
| Treatment Outcome | 5 | 2024 | 5834 | 0.170 |
Why?
|
| Disease Progression | 2 | 2017 | 1229 | 0.170 |
Why?
|
| Chromosomes, Human, Pair 22 | 1 | 2021 | 10 | 0.170 |
Why?
|
| High Mobility Group Proteins | 1 | 2021 | 27 | 0.170 |
Why?
|
| Flucytosine | 1 | 2020 | 2 | 0.170 |
Why?
|
| Cytosine Deaminase | 1 | 2020 | 6 | 0.170 |
Why?
|
| Cyclin D | 1 | 2020 | 4 | 0.160 |
Why?
|
| G1 Phase Cell Cycle Checkpoints | 1 | 2020 | 5 | 0.160 |
Why?
|
| Triazines | 1 | 2020 | 22 | 0.160 |
Why?
|
| Sulfones | 1 | 2020 | 43 | 0.160 |
Why?
|
| Receptors, Fibroblast Growth Factor | 1 | 2020 | 9 | 0.160 |
Why?
|
| Guanine | 1 | 2020 | 26 | 0.160 |
Why?
|
| Smad Proteins | 1 | 2020 | 23 | 0.160 |
Why?
|
| bcl-X Protein | 1 | 2020 | 24 | 0.160 |
Why?
|
| Mediator Complex | 1 | 2020 | 13 | 0.160 |
Why?
|
| Quinolines | 1 | 2020 | 47 | 0.160 |
Why?
|
| Benzamides | 1 | 2020 | 69 | 0.160 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2020 | 38 | 0.160 |
Why?
|
| Imidazoles | 1 | 2020 | 82 | 0.160 |
Why?
|
| Fatigue | 2 | 2022 | 114 | 0.160 |
Why?
|
| Retinoblastoma Protein | 1 | 2020 | 45 | 0.150 |
Why?
|
| Wnt2 Protein | 1 | 2019 | 1 | 0.150 |
Why?
|
| Anaplasia | 1 | 2019 | 2 | 0.150 |
Why?
|
| Azacitidine | 1 | 2019 | 15 | 0.150 |
Why?
|
| Caspase 3 | 1 | 2020 | 108 | 0.150 |
Why?
|
| Follow-Up Studies | 3 | 2026 | 2500 | 0.150 |
Why?
|
| Pyrazoles | 1 | 2020 | 88 | 0.150 |
Why?
|
| Dacarbazine | 2 | 2016 | 18 | 0.150 |
Why?
|
| Pyrimidines | 1 | 2020 | 144 | 0.150 |
Why?
|
| Status Epilepticus | 1 | 2019 | 24 | 0.150 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2019 | 65 | 0.150 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2026 | 314 | 0.150 |
Why?
|
| Gene Knockdown Techniques | 1 | 2019 | 206 | 0.150 |
Why?
|
| Molecular Targeted Therapy | 1 | 2019 | 129 | 0.150 |
Why?
|
| Pandemics | 1 | 2024 | 691 | 0.140 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2019 | 133 | 0.140 |
Why?
|
| In Vitro Techniques | 1 | 2019 | 491 | 0.140 |
Why?
|
| Signal Transduction | 3 | 2020 | 3170 | 0.140 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2020 | 198 | 0.140 |
Why?
|
| Reproducibility of Results | 3 | 2018 | 1719 | 0.140 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2019 | 54 | 0.140 |
Why?
|
| Injections, Spinal | 2 | 2017 | 44 | 0.140 |
Why?
|
| Down-Regulation | 1 | 2019 | 326 | 0.140 |
Why?
|
| Neoplasm Staging | 1 | 2020 | 554 | 0.140 |
Why?
|
| Neurofibromatosis 1 | 1 | 2018 | 30 | 0.140 |
Why?
|
| Cell Survival | 1 | 2020 | 588 | 0.140 |
Why?
|
| Cell Cycle | 1 | 2020 | 398 | 0.140 |
Why?
|
| Prognosis | 2 | 2026 | 1793 | 0.140 |
Why?
|
| Cell Death | 1 | 2019 | 289 | 0.140 |
Why?
|
| Therapies, Investigational | 1 | 2018 | 1 | 0.140 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2020 | 588 | 0.130 |
Why?
|
| Phosphorylation | 1 | 2019 | 963 | 0.130 |
Why?
|
| Leukemia | 1 | 2017 | 62 | 0.120 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 859 | 0.120 |
Why?
|
| Pituitary Neoplasms | 1 | 2016 | 21 | 0.120 |
Why?
|
| Wakefulness-Promoting Agents | 1 | 2016 | 1 | 0.120 |
Why?
|
| Neuroendocrine Tumors | 1 | 2016 | 20 | 0.120 |
Why?
|
| Cohort Studies | 5 | 2026 | 2651 | 0.120 |
Why?
|
| Spinal Cord Neoplasms | 1 | 2016 | 9 | 0.120 |
Why?
|
| Oligodendroglioma | 1 | 2016 | 7 | 0.120 |
Why?
|
| Adenoma | 1 | 2016 | 70 | 0.120 |
Why?
|
| Gamma Rays | 1 | 2015 | 32 | 0.120 |
Why?
|
| Cells, Cultured | 1 | 2020 | 2194 | 0.120 |
Why?
|
| Waldenstrom Macroglobulinemia | 1 | 2015 | 8 | 0.120 |
Why?
|
| S100 Proteins | 1 | 2015 | 20 | 0.110 |
Why?
|
| Longitudinal Studies | 2 | 2019 | 1294 | 0.110 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2015 | 42 | 0.110 |
Why?
|
| Benzhydryl Compounds | 1 | 2016 | 61 | 0.110 |
Why?
|
| Leukemia, B-Cell | 1 | 2015 | 6 | 0.110 |
Why?
|
| Receptor-Interacting Protein Serine-Threonine Kinases | 1 | 2015 | 84 | 0.110 |
Why?
|
| Necrosis | 1 | 2015 | 147 | 0.110 |
Why?
|
| Bone Neoplasms | 1 | 2016 | 124 | 0.110 |
Why?
|
| Radiation Injuries | 1 | 2015 | 67 | 0.110 |
Why?
|
| Myelin Basic Protein | 1 | 2015 | 20 | 0.110 |
Why?
|
| Oligopeptides | 1 | 2015 | 135 | 0.110 |
Why?
|
| Diagnosis, Differential | 2 | 2017 | 993 | 0.110 |
Why?
|
| Fourth Ventricle | 1 | 2014 | 3 | 0.110 |
Why?
|
| Neural Cell Adhesion Molecule L1 | 1 | 2014 | 4 | 0.110 |
Why?
|
| Gene Fusion | 1 | 2014 | 7 | 0.110 |
Why?
|
| Neoplasms, Neuroepithelial | 1 | 2014 | 6 | 0.110 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2015 | 50 | 0.110 |
Why?
|
| ErbB Receptors | 1 | 2015 | 128 | 0.110 |
Why?
|
| Autopsy | 1 | 2014 | 56 | 0.110 |
Why?
|
| Natalizumab | 1 | 2014 | 11 | 0.110 |
Why?
|
| Hair Dyes | 1 | 2014 | 5 | 0.110 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2015 | 70 | 0.110 |
Why?
|
| Lead Poisoning | 1 | 2014 | 10 | 0.100 |
Why?
|
| Methylprednisolone | 1 | 2014 | 37 | 0.100 |
Why?
|
| Dexamethasone | 1 | 2015 | 214 | 0.100 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2014 | 58 | 0.100 |
Why?
|
| Prednisone | 1 | 2014 | 83 | 0.100 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 1 | 2014 | 34 | 0.100 |
Why?
|
| Glutamates | 1 | 2013 | 13 | 0.100 |
Why?
|
| Spinal Cord | 1 | 2015 | 210 | 0.100 |
Why?
|
| Hypertrophy | 1 | 2013 | 29 | 0.100 |
Why?
|
| Severity of Illness Index | 2 | 2015 | 1569 | 0.100 |
Why?
|
| Child | 3 | 2026 | 4653 | 0.100 |
Why?
|
| X-linked Nuclear Protein | 2 | 2026 | 2 | 0.100 |
Why?
|
| Liver Neoplasms | 1 | 2016 | 310 | 0.100 |
Why?
|
| Fatal Outcome | 1 | 2013 | 122 | 0.100 |
Why?
|
| Adolescent | 3 | 2026 | 6368 | 0.100 |
Why?
|
| Riluzole | 1 | 2012 | 7 | 0.100 |
Why?
|
| Biopsy | 1 | 2014 | 463 | 0.090 |
Why?
|
| Occupational Therapy | 1 | 2012 | 12 | 0.090 |
Why?
|
| Arm | 1 | 2012 | 45 | 0.090 |
Why?
|
| Muscle Neoplasms | 1 | 2012 | 9 | 0.090 |
Why?
|
| NF-kappa B | 1 | 2014 | 436 | 0.090 |
Why?
|
| Hyaluronan Receptors | 1 | 2012 | 35 | 0.090 |
Why?
|
| Physical Therapy Modalities | 1 | 2012 | 46 | 0.090 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2014 | 169 | 0.090 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2012 | 94 | 0.090 |
Why?
|
| Aged, 80 and over | 2 | 2026 | 5682 | 0.090 |
Why?
|
| Young Adult | 5 | 2026 | 4883 | 0.090 |
Why?
|
| Neuroprotective Agents | 1 | 2012 | 80 | 0.090 |
Why?
|
| Viral Load | 1 | 2012 | 230 | 0.090 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2019 | 420 | 0.080 |
Why?
|
| Transcription, Genetic | 1 | 2014 | 911 | 0.080 |
Why?
|
| Texas | 2 | 2019 | 60 | 0.060 |
Why?
|
| Child, Preschool | 2 | 2026 | 2090 | 0.060 |
Why?
|
| Transcription Factors | 1 | 2014 | 1561 | 0.060 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2026 | 54 | 0.060 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2026 | 35 | 0.060 |
Why?
|
| Dioxygenases | 1 | 2026 | 36 | 0.060 |
Why?
|
| Prevalence | 2 | 2021 | 1454 | 0.060 |
Why?
|
| Disease-Free Survival | 2 | 2016 | 245 | 0.060 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2026 | 94 | 0.050 |
Why?
|
| DNA Helicases | 1 | 2026 | 202 | 0.050 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2026 | 304 | 0.050 |
Why?
|
| Survival Rate | 1 | 2026 | 849 | 0.050 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2026 | 344 | 0.050 |
Why?
|
| Everolimus | 1 | 2024 | 22 | 0.050 |
Why?
|
| Genomics | 1 | 2026 | 387 | 0.050 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 2022 | 17 | 0.050 |
Why?
|
| Dextroamphetamine | 1 | 2022 | 3 | 0.050 |
Why?
|
| Hydroxamic Acids | 1 | 2022 | 29 | 0.050 |
Why?
|
| Tissue Preservation | 1 | 2022 | 5 | 0.040 |
Why?
|
| Preservation, Biological | 1 | 2022 | 5 | 0.040 |
Why?
|
| Nuclear Proteins | 1 | 2026 | 793 | 0.040 |
Why?
|
| Lomustine | 1 | 2020 | 2 | 0.040 |
Why?
|
| Patient Care Team | 1 | 2024 | 338 | 0.040 |
Why?
|
| Standard of Care | 1 | 2020 | 29 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2022 | 183 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2020 | 17 | 0.040 |
Why?
|
| Cloning, Molecular | 1 | 2021 | 387 | 0.040 |
Why?
|
| Protein Domains | 1 | 2021 | 155 | 0.040 |
Why?
|
| Referral and Consultation | 1 | 2024 | 447 | 0.040 |
Why?
|
| DNA-Binding Proteins | 1 | 2026 | 1226 | 0.040 |
Why?
|
| Neurofibromin 1 | 1 | 2018 | 14 | 0.040 |
Why?
|
| Germ-Line Mutation | 1 | 2018 | 47 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 2020 | 710 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2022 | 1030 | 0.030 |
Why?
|
| RNA | 1 | 2022 | 427 | 0.030 |
Why?
|
| Biomarkers | 1 | 2024 | 1503 | 0.030 |
Why?
|
| Antigens, Neoplasm | 1 | 2018 | 134 | 0.030 |
Why?
|
| Universities | 1 | 2019 | 169 | 0.030 |
Why?
|
| Epithelial Cells | 1 | 2020 | 414 | 0.030 |
Why?
|
| Cell Membrane | 1 | 2020 | 506 | 0.030 |
Why?
|
| Cell Line | 1 | 2021 | 2031 | 0.030 |
Why?
|
| Subacute Combined Degeneration | 1 | 2017 | 1 | 0.030 |
Why?
|
| Homocysteine | 1 | 2017 | 33 | 0.030 |
Why?
|
| Folic Acid | 1 | 2017 | 42 | 0.030 |
Why?
|
| Quality of Life | 1 | 2024 | 1266 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2015 | 108 | 0.030 |
Why?
|
| Cancer Care Facilities | 1 | 2015 | 17 | 0.030 |
Why?
|
| Lymph Nodes | 1 | 2016 | 237 | 0.030 |
Why?
|
| Age of Onset | 1 | 2015 | 175 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2015 | 426 | 0.030 |
Why?
|
| Transcriptome | 1 | 2018 | 408 | 0.030 |
Why?
|
| Positron-Emission Tomography | 1 | 2016 | 233 | 0.030 |
Why?
|
| Caspases | 1 | 2015 | 176 | 0.030 |
Why?
|
| Risk Factors | 2 | 2015 | 5475 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2015 | 611 | 0.030 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2015 | 172 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2015 | 626 | 0.030 |
Why?
|
| Lead | 1 | 2014 | 46 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2020 | 1583 | 0.030 |
Why?
|
| T-Lymphocytes | 1 | 2018 | 1012 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2017 | 398 | 0.020 |
Why?
|
| Sex Factors | 1 | 2015 | 995 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2016 | 811 | 0.020 |
Why?
|
| Rats | 1 | 2015 | 2005 | 0.020 |
Why?
|
| Incidence | 1 | 2014 | 1433 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2015 | 1663 | 0.020 |
Why?
|